TransEnterix opens the doors to a competitive US surgical robotics market

This article was originally published here

Transenterix Senhance Surgical Robotic SystemThe surgical robotics market in the US has finally become competitive.

In October, the FDA granted clearance to only the second robotic surgical system to date – TransEnterix‘s (NYSE:TRXC) Senhance laparoscopic platform.

The clearance was a huge milestone for the Morrisville, N.C.-based company and was quickly followed by yet another – almost exactly a month after receiving a nod from the federal watchdog, TransEnterix logged its 1st sale of the platform to the Orlando-based Florida hospital.

Read the whole story on our sister site, The Robot Report

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply